[Decrease in mortality on spironolactone being added to the conventional treatment of heart failure].
作者信息
Soto Alvarez J
出版信息
Aten Primaria. 2000 Mar 15;25(4):282-4. doi: 10.1016/s0212-6567(00)78503-9.
Abstract
摘要
相似文献
1
[Decrease in mortality on spironolactone being added to the conventional treatment of heart failure].在心力衰竭常规治疗中加用螺内酯后死亡率的降低
Aten Primaria. 2000 Mar 15;25(4):282-4. doi: 10.1016/s0212-6567(00)78503-9.
2
[Aldosterone blockade in heart failure. So much for so little].[心力衰竭中的醛固酮阻断。收效甚微]
Med Clin (Barc). 2002 Jun 1;118(20):779-81. doi: 10.1016/s0025-7753(02)72528-1.
3
Spironolactone in heart failure--a revived role for an old drug.螺内酯在心力衰竭中的应用——一种老药的新角色
Intensive Crit Care Nurs. 2000 Dec;16(6):403-4. doi: 10.1054/iccn.2000.1544.
4
[Therapy of heart failure after myocardial infarction. With eplerenone a new course].心肌梗死后心力衰竭的治疗。使用依普利酮开启新疗程
MMW Fortschr Med. 2004 Oct 21;146(43):58-9.
5
Why does spironolactone improve mortality over and above an ACE inhibitor in chronic heart failure?在慢性心力衰竭中，与血管紧张素转换酶抑制剂相比，螺内酯为何能进一步降低死亡率？
Br J Clin Pharmacol. 1999 May;47(5):479-82. doi: 10.1046/j.1365-2125.1999.00954.x.
6
[Aldosterone and its antagonists in heart failure].[醛固酮及其拮抗剂在心力衰竭中的作用]
Presse Med. 2003 Jan 18;32(2):79-87.
7
[Aldosterone antagonists for all patients with heart failure?].[醛固酮拮抗剂适用于所有心力衰竭患者吗？]
MMW Fortschr Med. 2009 Apr 9;151(15):33-5.
8
[Aldosterone receptor blockade after acute myocardial infarction with heart failure].急性心肌梗死合并心力衰竭后的醛固酮受体阻断
Med Klin (Munich). 2006 Jun 15;101(6):458-66. doi: 10.1007/s00063-006-1063-3.
9
Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]).在血管紧张素转换酶抑制剂和袢利尿剂基础上加用螺内酯治疗重度慢性充血性心力衰竭的疗效（随机螺内酯评估研究[RALES]）
Am J Cardiol. 1996 Oct 15;78(8):902-7. doi: 10.1016/s0002-9149(96)00465-1.
10
Aldosterone antagonism in heart failure.心力衰竭中的醛固酮拮抗作用。
Lancet. 1999 Sep 4;354(9181):789-90. doi: 10.1016/S0140-6736(99)80003-8.
本文引用的文献
1
[The basic norms for managing heart failure in primary care].
Aten Primaria. 1999 Sep 30;24(5):289-94.
2
Aldosterone and spironolactone in heart failure.心力衰竭中的醛固酮与螺内酯
N Engl J Med. 1999 Sep 2;341(10):753-5. doi: 10.1056/NEJM199909023411009.
3
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.螺内酯对重度心力衰竭患者发病率和死亡率的影响。随机螺内酯评估研究调查组。
N Engl J Med. 1999 Sep 2;341(10):709-17. doi: 10.1056/NEJM199909023411001.
4
[Trends of morbidity and mortality in chronic heart failure in Catalonia].[加泰罗尼亚慢性心力衰竭的发病率和死亡率趋势]
Rev Esp Cardiol. 1998 Dec;51(12):972-6. doi: 10.1016/s0300-8932(98)74849-3.
5
[Costs of chronic heart failure in spain].[西班牙慢性心力衰竭的成本]
An Med Interna. 1997 Jan;14(1):9-14.
6
Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]).在血管紧张素转换酶抑制剂和袢利尿剂基础上加用螺内酯治疗重度慢性充血性心力衰竭的疗效（随机螺内酯评估研究[RALES]）
Am J Cardiol. 1996 Oct 15;78(8):902-7. doi: 10.1016/s0002-9149(96)00465-1.
Zotero 插件